Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-08-29
2006-08-29
Siew, Jeffrey (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S130100, C424S134100, C424S135100, C424S138100, C424S141100, C424S142100, C424S155100, C424S156100
Reexamination Certificate
active
07097836
ABSTRACT:
The present invention provides a method for enhancing the efficacy of chemotherapeutic agents for therapy of cancer and other angiogenesis-associated diseases such as rheumatoid arthritis. The method comprises the steps of administering to an individual in need of treatment, a combination of an anti-endoglin antibody and a chemotherapeutic agent. The anti-endoglin antibody and the chemotherapeutic agent may be administered sequentially or concurrently.
REFERENCES:
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 6190660 (2001-02-01), Seon
Wiesenthal (http://weisenthal.org/feedback. html, Feb. 4, 2002).
Maier et al. (Anti-Cancer Drugs 1997; 8: 238-244).
Holmes (Seminars in Oncology 1996; 23: 46-56).
Seon (Int. J. Cancer 2002; 99: 310-311).
Takahashi et al. (Cancer Research 2001; 61: 7846-7854).
Biddle et al. (Leukemia Research 1989; 13: 699-707).
Buhring et al.Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia, 5: 841-847, 1991.
Burrows et al.Up-regulation of Endoglin on Vascular Endothelial Cells in Human Solid Tumors: Implications for Diagnosis and Therapy, Clin. Cancer Res., 1: 1623-1634, 1995.
Cheifetz et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J. Biol. Chem., 267: 19027-19030, 1992.
Fonsatti et al.Endoglin is a suitable target for efficieent imaging of solid tumors: In vivo evidence in a canine mammary carcinoma model. Clin. Cancer Res., 6: 2037-2043, 2000.
Gougos et al.Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J. Immunol., 141: 1925-1933, 1988.
Haruta et al.Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc. Natl. Acad. Sci. U S A, 83: 7898-7902, 1986.
Lastres et al.Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp- containing surface antigen.Eur. J. Immunol., 22: 393-397, 1992.
Li et al.Defective angiogenesis in mice lacking endoglin. Science, 284: 1534-1537, 1999.
Matsuzaki et al.Effect of Induced Transformation of Human Leukemia Cells on the Expression of GP160, A Novel Human Leukemia-Associated Cell Surface Glycoprotein, Fed. Proc. 46: 1056, 1987.
Matsuno et al.Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin. Cancer Res., 5: 371-382, 1999.
Miller et al.Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int. J. Cancer, 81: 568-572, 1999.
Rokhlin et al.Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J. Immunol., 154: 4456-4465, 1995.
Seon et al.CD105 Workshop: Immunohistochemical detection of CD105 in the vascular endothelium of human malignant and non-malignant tissues. In: T. Kishimoto, H. Kikutani, A. E. G. Kr. Von dem Borne, S. Goyert, D.Mason, M. Miyasaka, L. Moretta, K. Okumura, S. Shaw, T. A. Springer, K. Sugamura, and H. Zola (eds.) Leukocyte Typing VI: White Cell Differentiation Antigens, pp. 709-710. New York: Garland Publishing, Inc., 1998.
Seon et al.Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin. Cancer Res., 3: 1031-1044, 1997.
Tabata et al.Antiangiogenic radioimmunotherapy of human solid tumors in SCD mice using125I-labeled anti-endoglin monoclonal antibodies. Int. J. Cancer, 82: 737-742, 1999.
Wang et al.A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int. J. Cancer, 54: 363-370, 1993.
Fetterolf Brandon
Health Research , Inc.
Hodgson & Russ LLP
Siew Jeffrey
LandOfFree
Method for increasing the efficacy of anti-tumor agents by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for increasing the efficacy of anti-tumor agents by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for increasing the efficacy of anti-tumor agents by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3626321